Company Vericel Corporation

Equities

VCEL

US92346J1088

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
52.02 USD -0.59% Intraday chart for Vericel Corporation +11.42% +46.08%

Business Summary

Vericel Corporation is engaged in advanced therapies for the sports medicine and severe burn care markets. The Company markets two cell therapy products and one specialty biologic product in the United States. MACI (autologous cultured chondrocytes onporcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single ormultiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

Sales per Business

USD in Million2022Weight2023Weight Delta
MACI
83.4 %
132 80.3 % 165 83.4 % +24.88%
Epicel
16.0 %
32 19.3 % 32 16.0 % -0.49%
NexoBrid
0.6 %
1 0.4 % 1 0.6 % +71.21%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
164 100.0 % 198 100.0 % +20.17%

Managers

Managers TitleAgeSince
Chief Executive Officer 60 13-02-28
Director of Finance/CFO 49 21-01-24
Chief Operating Officer 62 17-04-09
Chief Tech/Sci/R&D Officer 61 18-08-19
Investor Relations Contact - -
Corporate Officer/Principal - 10-12-31
Comptroller/Controller/Auditor 45 21-08-31
Corporate Officer/Principal - 21-09-06
General Counsel 50 19-11-05
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 15-01-05
Director/Board Member 67 15-01-05
Chairman 73 06-01-15
Chief Executive Officer 60 13-02-28
Director/Board Member 69 05-09-27
Director/Board Member 71 15-01-05
Director/Board Member 55 13-08-22
Director/Board Member 49 21-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 48,380,458 47,977,912 ( 99.17 %) 0 99.17 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
15.92 %
7,599,600 15.92 % 347 M $
Brown Capital Management LLC
14.29 %
6,818,933 14.29 % 311 M $
Vanguard Fiduciary Trust Co.
7.070 %
3,374,093 7.070 % 154 M $
RTW Investments LP
6.732 %
3,212,794 6.732 % 147 M $
2,664,883 5.584 % 122 M $
Conestoga Capital Advisors LLC
5.229 %
2,495,619 5.229 % 114 M $
Conestoga Capital Advisors LLC
4.903 %
2,339,960 4.903 % 107 M $
BNY Mellon Investment Adviser, Inc.
3.526 %
1,682,778 3.526 % 77 M $
Eaton Vance Management
2.719 %
1,297,846 2.719 % 59 M $
Macquarie Investment Management Business Trust
2.402 %
1,146,193 2.402 % 52 M $

Company contact information

Vericel Corp.

64 Sidney Street

02139-4170, Cambridge

+617 588 5555

http://www.vcel.com
address Vericel Corporation(VCEL)